ThermoGenesis (THMO) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 10, 2018
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	811,212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		20,649,147
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,071,000	$ 3,513,000
Accounts receivable, net of allowance for doubtful accounts of $281,000 ($274,000 at December 31, 2017)	1,814,000	1,687,000
Accounts receivable – related party	30,000	862,000
Inventories, net of reserves of $0 ($1,069,000 at December 31, 2017)	5,156,000	4,798,000
Prepaid expenses and other current assets	335,000	594,000
Total current assets	10,406,000	11,454,000
Restricted cash	1,000,000	1,000,000
Equipment, net	3,466,000	2,996,000
Goodwill	1,281,000	13,976,000
Intangible assets, net	7,039,000	21,629,000
Other assets	51,000	56,000
Total assets	23,243,000	51,111,000
Current liabilities:
Accounts payable	2,048,000	2,079,000
Accrued payroll and related expenses	581,000	532,000
Deferred revenue	718,000	384,000
Related party payable		606,000
Other current liabilities	2,053,000	1,863,000
Total current liabilities	5,400,000	5,464,000
Long-term debt-related party	7,200,000	6,700,000
Noncurrent deferred tax liability	1,279,000	4,730,000
Derivative obligations	30,000	597,000
Other non-current liabilities	371,000	408,000
Total liabilities	14,280,000	17,899,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 20,649,147 issued and outstanding (10,872,428 at December 31, 2017)	21,000	11,000
Paid in capital in excess of par	227,694,000	221,371,000
Accumulated deficit	(217,337,000)	(187,640,000)
Accumulated other comprehensive loss	(15,000)	(43,000)
Total Cesca Therapeutics Inc. stockholders’ equity	10,363,000	33,699,000
Noncontrolling interests	(1,400,000)	(487,000)
Total equity	8,963,000	33,212,000
Total liabilities and stockholders’ equity	$ 23,243,000	$ 51,111,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 281,000	$ 274,000
Inventories, reserves		$ 1,069,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	20,649,147	10,872,428
Common stock, shares outstanding (in shares)	20,649,147	10,872,428

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net revenues	$ 2,004,000	$ 3,501,000	$ 3,871,000	$ 6,753,000
Cost of revenues	1,641,000	1,973,000	3,156,000	3,848,000
Gross profit	363,000	1,528,000	715,000	2,905,000
Expenses:
Sales and marketing	359,000	421,000	685,000	756,000
Research and development	908,000	566,000	1,949,000	1,133,000
General and administrative	2,399,000	1,963,000	4,641,000	4,601,000
Impairment of intangible asset	27,202,000	310,000	27,202,000	310,000
Total operating expenses	30,868,000	3,260,000	34,477,000	6,800,000
Loss from operations	(30,505,000)	(1,732,000)	(33,762,000)	(3,895,000)
Interest expense	(383,000)	(112,000)	(743,000)	(131,000)
Change in fair value of derivative instruments	308,000	44,000	567,000	113,000
Other expenses	(32,000)	(27,000)	(44,000)	(11,000)
Total other expense	(107,000)	(95,000)	(220,000)	(29,000)
Loss before benefit for income taxes	(30,612,000)	(1,827,000)	(33,982,000)	(3,924,000)
Benefit for income taxes	3,451,000	673,000	3,451,000	673,000
Net loss	(27,161,000)	(1,154,000)	(30,531,000)	(3,251,000)
Loss attributable to noncontrolling interests	(503,000)		(913,000)
Net loss attributable to common stockholders	(26,658,000)	(1,154,000)	(29,618,000)	(3,251,000)
Net loss	(27,161,000)	(1,154,000)	(30,531,000)	(3,251,000)
Foreign currency translation adjustments	21,000	1,000	28,000	(1,000)
Comprehensive loss	(27,140,000)	(1,153,000)	(30,503,000)	(3,252,000)
Comprehensive loss attributable to noncontrolling interests	(503,000)		(913,000)
Comprehensive loss attributable to common stockholders	$ (26,637,000)	$ (1,153,000)	$ (29,590,000)	$ (3,252,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (1.73)	$ (0.12)	$ (2.25)	$ (0.33)
Weighted average common shares outstanding – basic and diluted (in shares)	15,444,120	9,909,056	13,184,375	9,898,304

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (30,531,000)	$ (3,251,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	333,000	357,000
Stock based compensation expense	300,000	428,000
Recovery of reserve for excess and slow-moving inventories	(252,000)	(144,000)
Change in fair value of derivative	(567,000)	(113,000)
Deferred income tax benefit	3,451,000	673,000
Loss on disposal of equipment	420,000	176,000
Impairment of intangible asset	27,202,000	310,000
Net change in operating assets and liabilities:
Accounts receivable	869,000	(671,000)
Inventories	(358,000)	(196,000)
Prepaid expenses and other current assets	257,000	37,000
Accounts payable	(242,000)	(475,000)
Related party payable	(606,000)	606,000
Accrued payroll and related expenses	50,000	(1,235,000)
Deferred revenue	254,000	194,000
Other current liabilities	217,000	(41,000)
Other noncurrent liabilities	3,000	46,000
Net cash used in operating activities	(6,102,000)	(4,645,000)
Capital expenditures	(850,000)	(99,000)
Net cash used in investing activities	(850,000)	(99,000)
Cash flows from financing activities:
Payments on capital lease obligations	(19,000)	(24,000)
Proceeds from long-term related party debt	500,000	3,500,000
Payment of financing cost		(13,000)
Proceeds from issuance of common stock, net	6,032,000
Net cash provided by financing activities	6,513,000	3,463,000
Effects of foreign currency rate changes on cash and cash equivalents	(3,000)	5,000
Net change in cash and cash equivalents	(442,000)	(1,276,000)
Cash and cash equivalents at beginning of period	3,513,000	4,899,000
Cash and cash equivalents at end of period	3,071,000	3,623,000
Supplemental disclosures of cash flow information:
Cash paid for interest	657,000
Supplemental non-cash financing and investing information:
Transfer of equipment to inventories	172,000	625,000
Transfer of inventories to equipment	$ 420,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company was founded in 1986 ® ® Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Liquidity and Going Concern The Company has a Revolving Credit Agreement (the “Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 4 June 30, 2018, $7,200,000 $10,000,000 may On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,819,000 $681,000. one $0.001 one one one one one one $0.60 five As of June 30, 2018, 2,691,666 May 2018 At June 30, 2018, $3,071,000 $5,006,000. June 30, 2018 $217,337,000. one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of Cesca, its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10 10 X. six June 30, 2018, not may December 31, 2018. 10 December 31, 2017. Reclassification Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Issued Accounting Standards In January 2017, 2017 04 Simplifying the Test for Goodwill Impairment 2 December 15, 2019. January 1, 2017. not 2017 04 In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 not 2016 02 Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 4 Sequencing Policy Under ASC 815 40 35, 815 first 815, not On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 not January 1, 2018. January 1, 2018 No. 2014 09, not 605 $79,000 January 1, 2018 606, 606 Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP ®, X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 June 30, 2018, $269,000 may The following table summarizes the revenues of the Company’s reportable segments for the three six June 30, 2018: Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 879,000 $ 66,000 $ -- $ 945,000 BioArchive 449,000 311,000 -- 760,000 Manual Disposables 229,000 -- -- 229,000 Other 8,000 -- 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Manual Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,564,000 $ 131,000 $ -- $ 1,695,000 BioArchive 872,000 655,000 -- 1,527,000 Manual Disposables 462,000 -- -- 462,000 Other 46,000 -- 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Manual Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the titles of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not $207,000. $384,000 $718,000 six June 30, 2018 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 749,000 $ 683,000 $ 209,000 $ -- $ 1,641,000 Clinical revenue 7,000 15,000 15,000 232,000 269,000 Total $ 756,000 $ 698,000 $ 224,000 $ 232,000 $ 1,910,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Goodwill, Intangible Assets and Im pairment Assessments For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not ASC) 350, not 50 2 In the second 2018, June 30, 2018 3 The Company recorded an impairment charge of $12,695,000 $14,507,000 June 30, 2018, Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (83,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at June 30, 2018, net $ 7,039,000 $ 1,281,000 Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Division, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Division, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 13,197,267 3,725,782 Stock options 1,200,470 397,388 Restricted stock units -- 59,694 Total 15,500,678 5,285,805 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen Inc.	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisition of SynGen Inc. On July 7, 2017, The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The consideration for the Transaction consisted of $1,000,000 2,000,000 20% $2,528,000. 2,000,000 first Supplemental Pro Forma Data The Company used the acquisition method of accounting to account for the SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. For the three six June 30, 2018, $19,000 $49,000 three six June 30, 2017 January 1, 2017. Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Net revenues $ 3,758,000 $ 7,138,000 Net loss $ (1,712,000 ) $ (3,960,000 ) Basic and diluted net loss per common share $ (0.17 ) $ (0.40 ) The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4. Related Party Transactions Revolving Credit Agreement On March 6, 2017, $10,000,000 March 6, 2022 ( $7,200,000 June 30, 2018. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued but unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% The Credit Agreement and Note were amended on April 16, 2018. ● The Lender was granted the right to convert, at any time, outstanding principal and accrued but unpaid interest under the Credit Agreement into shares of Common Stock at a conversion price equal to $1.61 90% 10 April 2018 ● If the Company after April 16, 2018 ● The Company has been granted the right to defer payment of the $657,000 December 31, 2017 December 31, 2018, $5.0 On May 7, 2018, No. 1 No. 1 On May 18, 2018, $0.60 $1.61 $0.60. The Maturity Date of the Amended Credit Agreement is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Amended Credit Agreement continuing to be true at all times and there being no No The Company accounted for the Amended Credit Agreement as a loan modification. As discussed in Note 2, 2017 11 Accounting for Certain Financial Instruments with Down Round Features”. 2017 11 not not not June 30, 2018, $0.60 not no June 30, 2018. The Company recorded interest expense of $382,000 $742,000 three six June 30, 2018, $103,000 $122,000 three six June 30, 2017, $742,000 $657,000 June 30, 2018 December 31, 2017, Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues During the three six June 30, 2018, $43,000 $269,000 $0 three six June 30 2017 Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (Payor), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no $606,000 $606,000 June 30, 2018.

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5 . Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. June 30, 2018. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the six June 30, 2018 Balance at December 31, 2017 $ 291,000 Warranties issued during the period 30,000 Settlements made during the period (216,000 ) Changes in liability for pre-existing warranties during the period (5,000 ) Balance at June 30, 2018 $ 100,000 Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 June 26, 2018. No no June 30, 2018. On January 31, 2018, not February 16, 2018. 609,636 304,818 March 28, 2018. 8% March 2018 8% August 16, 2018. On June 1, 2018, January 31, 2018 no $150,000 June 2018 six first In the normal course of operations, the Company may June 30, 2018, may not

Note 6 - Derivative Obligations

Note 6 - Derivative Obligations	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	6. Derivative Obligations Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. Series A June 30, 2018 December 31, 2017 Market price of common stock $ 0.42 $ 3.00 Expected volatility 111.2 % 107 % Contractual term (years) 2.7 3.2 Discount rate 2.60 % 1.99 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain of $308,000 $567,000 three six June 30, 2018, $44,000 $113,000 three six June 30, 2017, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2018 December 31, 2017: Derivative Obligation June 30, 2018 December 31, 2017 Balance $ 30,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 30,000 $ 597,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the six June 30, 2018: Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (567,000 ) Balance – June 30, 2018 $ 30,000

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Stockholders’ Equity Common Stock On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,819,000 $681,000. one one one one one one one $0.60 five As of June 30, 2018, 2,691,666 May 2018 On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six 5.5 Stock Based Compensation The Company recorded stock-based compensation of $163,000 $300,000 three six June 30, 2018, $181,000 $428,000 three six June 30, 2017, The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 93,500 $ 2.63 Forfeited (21,875 ) $ 3.26 Expired (27,182 ) $ 4.67 Outstanding at June 30, 2018 1,200,470 $ 3.81 8.4 -- Vested and expected to vest at June 30, 2018 960,726 $ 4.02 8.1 -- Exercisable at June 30, 2018 303,348 $ 6.26 5.5 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no six June 30, 2018. The fair value of the Company’s stock options granted for the six June 30, 2018 Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 % Common Stock Restricted Units The following is a summary of restricted stock activity during the six June 30, 2018: Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- -- Vested 416 17.60 Forfeited -- -- Outstanding at June 30, 2018 -- -- Warrants A summary of warrant activity for the six June 30, 2018 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $ 9.37 Warrants granted 9,471,485 0.67 Warrants canceled -- -- Warrants exercised -- -- Outstanding at June 30, 2018 14,300,208 $ 3.61 Exercisable at June 30, 2018 13,296,861 $ 3.40 At June 30, 2018, $0.

Note 8 - Segment Reporting

Note 8 - Segment Reporting	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8. Segment Reporting The Company has two The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The following table summarizes the operating results of the Company’s reportable segments: Three Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 46,000 $ 1,958,000 $ 2,004,000 Cost of revenues 49,000 1,592,000 1,641,000 Gross profit (3,000 ) 366,000 363,000 Operating expenses 28,408,000 2,460,000 30,868,000 Operating loss $ (28,411,000 ) $ (2,094,000 ) $ (30,505,000 ) Depreciation and amortization $ 69,000 $ 105,000 $ 174,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 122,000 $ 41,000 $ 163,000 Three Months Ended June 30, 2017 Clinical Development Device Total Net revenues $ 113,000 $ 3,388,000 $ 3,501,000 Cost of revenues 111,000 1,862,000 1,973,000 Gross profit 2,000 1,526,000 1,528,000 Operating expenses 1,899,000 1,361,000 3,260,000 Operating loss $ (1,897,000 ) $ 165,000 $ (1,732,000 ) Depreciation and amortization $ 110,000 $ 62,000 $ 172,000 Stock-based compensation expense $ 100,000 $ 81,000 $ 181,000 Six Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 108,000 $ 3,763,000 $ 3,871,000 Cost of revenues 120,000 3,036,000 3,156,000 Gross profit (12,000 ) 727,000 715,000 Operating expenses 29,588,000 4,889,000 34,477,000 Operating loss $ (29,600,000 ) $ (4,162,000 ) $ (33,762,000 ) Depreciation and amortization $ 137,000 $ 196,000 $ 333,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 220,000 $ 80,000 $ 300,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000 Six Months Ended June 30, 2017 Clinical Development Device Total Net revenues $ 266,000 $ 6,487,000 $ 6,753,000 Cost of revenues 235,000 3,613,000 3,848,000 Gross profit 31,000 2,874,000 2,905,000 Operating expenses 3,880,000 2,920,000 6,800,000 Operating loss $ (3,849,000 ) $ (46,000 ) $ (3,895,000 ) Depreciation and amortization $ 226,000 $ 131,000 $ 357,000 Stock-based compensation expense $ 251,000 $ 177,000 $ 428,000

Note 9 - Income Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income Taxes The following table summarizes our benefit for income taxes and our effective tax rates for the three six June 30, 2018. Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 Net loss before benefit for income taxes $ (30,612,000 ) $ (33,982,000 ) Benefit for income taxes 3,451,000 3,451,000 Effective tax rate 11.3 % 10.2 % For the three June 30, 2018, $3,451,000 three June 30, 2018. For the six June 30, 2018, $3,451,000. The Tax Cuts and Jobs Act (Jobs Act) legislation was passed in December 2017, 35% 21% June 30, 2018, not not may may may

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In January 2017, 2017 04 Simplifying the Test for Goodwill Impairment 2 December 15, 2019. January 1, 2017. not 2017 04 In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 not 2016 02 Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 4 Sequencing Policy Under ASC 815 40 35, 815 first 815, not On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 not January 1, 2018. January 1, 2018 No. 2014 09, not 605 $79,000 January 1, 2018 606, 606
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Disaggregation of Revenue The Company’s primary revenue streams include device sales, service revenue from device maintenance contracts and clinical services. Device Sales Device sales include devices and consumables for BioArchive, AXP ®, X not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and X one two X one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage in our clinical segment. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 June 30, 2018, $269,000 may The following table summarizes the revenues of the Company’s reportable segments for the three six June 30, 2018: Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 879,000 $ 66,000 $ -- $ 945,000 BioArchive 449,000 311,000 -- 760,000 Manual Disposables 229,000 -- -- 229,000 Other 8,000 -- 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Manual Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,564,000 $ 131,000 $ -- $ 1,695,000 BioArchive 872,000 655,000 -- 1,527,000 Manual Disposables 462,000 -- -- 462,000 Other 46,000 -- 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Manual Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000 Performance Obligations There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances The Company records a receivable when the titles of goods have transferred, maintenance contracts have been fully executed or when services have been rendered. Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not $207,000. $384,000 $718,000 six June 30, 2018 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 749,000 $ 683,000 $ 209,000 $ -- $ 1,641,000 Clinical revenue 7,000 15,000 15,000 232,000 269,000 Total $ 756,000 $ 698,000 $ 224,000 $ 232,000 $ 1,910,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill, Intangible Assets and Im pairment Assessments For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not ASC) 350, not 50 2 In the second 2018, June 30, 2018 3 The Company recorded an impairment charge of $12,695,000 $14,507,000 June 30, 2018, Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (83,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at June 30, 2018, net $ 7,039,000 $ 1,281,000
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Division, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Division, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 13,197,267 3,725,782 Stock options 1,200,470 397,388 Restricted stock units -- 59,694 Total 15,500,678 5,285,805 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 2 - Summary of Significa16

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 879,000 $ 66,000 $ -- $ 945,000 BioArchive 449,000 311,000 -- 760,000 Manual Disposables 229,000 -- -- 229,000 Other 8,000 -- 16,000 24,000 Total Device Segment 1,565,000 377,000 16,000 1,958,000 Clinical Development Segment: Manual Disposables 1,000 -- -- 1,000 Bone Marrow -- 38,000 -- 38,000 Other -- 7,000 -- 7,000 Total Clinical Development 1,000 45,000 -- 46,000 Total $ 1,566,000 $ 422,000 $ 16,000 $ 2,004,000 Six Months Ended June 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,564,000 $ 131,000 $ -- $ 1,695,000 BioArchive 872,000 655,000 -- 1,527,000 Manual Disposables 462,000 -- -- 462,000 Other 46,000 -- 33,000 79,000 Total Device Segment 2,944,000 786,000 33,000 3,763,000 Clinical Development Segment: Manual Disposables 23,000 -- -- 23,000 Bone Marrow -- 61,000 -- 61,000 Other -- 24,000 -- 24,000 Total Clinical Development 23,000 85,000 -- 108,000 Total $ 2,967,000 $ 871,000 $ 33,000 $ 3,871,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2018 2019 2020 2021 and beyond Total Service revenue $ 749,000 $ 683,000 $ 209,000 $ -- $ 1,641,000 Clinical revenue 7,000 15,000 15,000 232,000 269,000 Total $ 756,000 $ 698,000 $ 224,000 $ 232,000 $ 1,910,000
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (83,000 ) -- Impairment loss (14,507,000 ) (12,695,000 ) Balance at June 30, 2018, net $ 7,039,000 $ 1,281,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2018 2017 Vested Series A warrants 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 Warrants – other 13,197,267 3,725,782 Stock options 1,200,470 397,388 Restricted stock units -- 59,694 Total 15,500,678 5,285,805

Note 3 - Acquisition of SynGe17

Note 3 - Acquisition of SynGen Inc. (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Net revenues $ 3,758,000 $ 7,138,000 Net loss $ (1,712,000 ) $ (3,960,000 ) Basic and diluted net loss per common share $ (0.17 ) $ (0.40 )

Note 5 - Commitments and Cont18

Note 5 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2017 $ 291,000 Warranties issued during the period 30,000 Settlements made during the period (216,000 ) Changes in liability for pre-existing warranties during the period (5,000 ) Balance at June 30, 2018 $ 100,000

Note 6 - Derivative Obligatio19

Note 6 - Derivative Obligations (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A June 30, 2018 December 31, 2017 Market price of common stock $ 0.42 $ 3.00 Expected volatility 111.2 % 107 % Contractual term (years) 2.7 3.2 Discount rate 2.60 % 1.99 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation June 30, 2018 December 31, 2017 Balance $ 30,000 $ 597,000 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ 30,000 $ 597,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2017 $ 597,000 Change in fair value of derivative obligation (567,000 ) Balance – June 30, 2018 $ 30,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2017 1,156,027 $ 3.92 Granted 93,500 $ 2.63 Forfeited (21,875 ) $ 3.26 Expired (27,182 ) $ 4.67 Outstanding at June 30, 2018 1,200,470 $ 3.81 8.4 -- Vested and expected to vest at June 30, 2018 960,726 $ 4.02 8.1 -- Exercisable at June 30, 2018 303,348 $ 6.26 5.5 --
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected life (years) 5.6 Risk-free interest rate 2.7 % Expected volatility 98 % Dividend yield 0 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Weighted Average Number of Shares Grant Date Fair Value Balance at December 31, 2017 416 $ 17.60 Granted -- -- Vested 416 17.60 Forfeited -- -- Outstanding at June 30, 2018 -- --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2017 4,828,723 $ 9.37 Warrants granted 9,471,485 0.67 Warrants canceled -- -- Warrants exercised -- -- Outstanding at June 30, 2018 14,300,208 $ 3.61 Exercisable at June 30, 2018 13,296,861 $ 3.40

Note 8 - Segment Reporting (Tab

Note 8 - Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 46,000 $ 1,958,000 $ 2,004,000 Cost of revenues 49,000 1,592,000 1,641,000 Gross profit (3,000 ) 366,000 363,000 Operating expenses 28,408,000 2,460,000 30,868,000 Operating loss $ (28,411,000 ) $ (2,094,000 ) $ (30,505,000 ) Depreciation and amortization $ 69,000 $ 105,000 $ 174,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 122,000 $ 41,000 $ 163,000 Three Months Ended June 30, 2017 Clinical Development Device Total Net revenues $ 113,000 $ 3,388,000 $ 3,501,000 Cost of revenues 111,000 1,862,000 1,973,000 Gross profit 2,000 1,526,000 1,528,000 Operating expenses 1,899,000 1,361,000 3,260,000 Operating loss $ (1,897,000 ) $ 165,000 $ (1,732,000 ) Depreciation and amortization $ 110,000 $ 62,000 $ 172,000 Stock-based compensation expense $ 100,000 $ 81,000 $ 181,000 Six Months Ended June 30, 2018 Clinical Development Device Total Net revenues $ 108,000 $ 3,763,000 $ 3,871,000 Cost of revenues 120,000 3,036,000 3,156,000 Gross profit (12,000 ) 727,000 715,000 Operating expenses 29,588,000 4,889,000 34,477,000 Operating loss $ (29,600,000 ) $ (4,162,000 ) $ (33,762,000 ) Depreciation and amortization $ 137,000 $ 196,000 $ 333,000 Impairment Charges $ 27,202,000 $ -- $ 27,202,000 Stock-based compensation expense $ 220,000 $ 80,000 $ 300,000 Goodwill $ 500,000 $ 781,000 $ 1,281,000 Total assets $ 12,808,000 $ 10,435,000 $ 23,243,000 Six Months Ended June 30, 2017 Clinical Development Device Total Net revenues $ 266,000 $ 6,487,000 $ 6,753,000 Cost of revenues 235,000 3,613,000 3,848,000 Gross profit 31,000 2,874,000 2,905,000 Operating expenses 3,880,000 2,920,000 6,800,000 Operating loss $ (3,849,000 ) $ (46,000 ) $ (3,895,000 ) Depreciation and amortization $ 226,000 $ 131,000 $ 357,000 Stock-based compensation expense $ 251,000 $ 177,000 $ 428,000

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 Net loss before benefit for income taxes $ (30,612,000 ) $ (33,982,000 ) Benefit for income taxes 3,451,000 3,451,000 Effective tax rate 11.3 % 10.2 %

Note 1 - Basis of Presentatio23

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	May 18, 2018	Mar. 28, 2018	Jun. 30, 2018	Dec. 31, 2017
Units Issued, Price per Unit	$ 0.60
Proceeds from Issuance or Sale of Equity, Total	$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net	4,819,000
Payments of Stock Issuance Costs	$ 681,000	$ 171,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 3,071,000	$ 3,513,000
Working Capital			5,006,000
Retained Earnings (Accumulated Deficit), Ending Balance			$ (217,337,000)	$ (187,640,000)
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.60
Warrants and Rights Outstanding, Term	5 years
Units [Member]
Number of Units Issued	6,475,001
Convertible Units, Number of Common Shares Called by Each Unit	1
Convertible Units, Number of Common Warrants Called by Each Unit	1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Pre-funded Units [member]
Number of Units Issued	2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit	1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit	1
Number of Units Exercised			2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total			$ 7,200,000
Line of Credit Facility, Maximum Borrowing Capacity			$ 10,000,000

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Jan. 01, 2018USD ($)
Maximum Period Of Agreement			21 years
Contract with Customer, Liability, Revenue Recognized		$ 207,000	$ 269,000
Contract with Customer, Liability, Current	$ 718,000	$ 384,000	$ 718,000
Goodwill, Impairment Loss	12,695,000
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 14,507,000
Number of Reportable Segments			2
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (79,000)

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net revenues	$ 2,004,000	$ 3,501,000	$ 3,871,000	$ 6,753,000
Device [Member]
Net revenues	1,958,000		3,763,000
Device [Member] | AXP [Member]
Net revenues	945,000		1,695,000
Device [Member] | BioArchive [Member]
Net revenues	760,000		1,527,000
Device [Member] | Manual Disposables [Member]
Net revenues	229,000		462,000
Device [Member] | Other Subsegments [Member]
Net revenues	24,000		79,000
Device [Member] | Bone Marrow [Member]
Net revenues	38,000		61,000
Clinical Development [Member]
Net revenues	46,000		108,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	1,000		23,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	7,000		24,000
Device Revenue [Member]
Net revenues	1,566,000		2,967,000
Device Revenue [Member] | Device [Member]
Net revenues	1,565,000		2,944,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	879,000		1,564,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	449,000		872,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	229,000		462,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	8,000		46,000
Device Revenue [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member]
Net revenues	1,000		23,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	1,000		23,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Service [Member]
Net revenues	422,000		871,000
Service [Member] | Device [Member]
Net revenues	377,000		786,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	66,000		131,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	311,000		655,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Device [Member] | Bone Marrow [Member]
Net revenues	38,000		61,000
Service [Member] | Clinical Development [Member]
Net revenues	45,000		85,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	7,000		24,000
Other [Member]
Net revenues	16,000		33,000
Other [Member] | Device [Member]
Net revenues	16,000		33,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	16,000		33,000
Other [Member] | Device [Member] | Bone Marrow [Member]
Net revenues
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Jun. 30, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue	$ 756,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	698,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	224,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue	232,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	1,910,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue	749,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	683,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	209,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	1,641,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue	7,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue	15,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue	15,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue	232,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue	$ 269,000

Note 2 - Summary of Significa27

Note 2 - Summary of Significant Accounting Policies - Goodwill and Intangible Assets (Details)	3 Months Ended
	Jun. 30, 2018USD ($)
Intangible assets at December 31, 2017, net	$ 21,629,000
Intangible assets, amortization and foreign exchange (current year)	(83,000)
Intangible assets, impairment loss	(14,507,000)
Intangible assets at June 30, 2018, net	7,039,000
Goodwill at December 31, 2017, net	13,976,000
Goodwill, impairment loss	(12,695,000)
Goodwill at June 30, 2018, net	$ 1,281,000

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017
Anti-dilutive securities (in shares)		15,500,678	5,285,805
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		13,197,267	3,725,782
Employee Stock Option [Member]
Anti-dilutive securities (in shares)		1,200,470	397,388
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)			59,694
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Acquisition of SynGe29

Note 3 - Acquisition of SynGen Inc. (Details Textual) - SynGen [Member] - USD ($)	Jul. 07, 2017	Jun. 30, 2018	Jun. 30, 2018
Payments to Acquire Businesses, Gross	$ 1,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,528,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		$ 19,000	$ 49,000

Note 3 - Acquisition of SynGe30

Note 3 - Acquisition of SynGen Inc.- Supplemental Pro Forma Data (Details) - SynGen [Member] - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Net revenues	$ 3,758,000	$ 7,138,000
Net loss	$ (1,712,000)	$ (3,960,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.17)	$ (0.40)

Note 4 - Related Party Transa31

Note 4 - Related Party Transactions (Details Textual) - USD ($)	Aug. 21, 2017	Jun. 30, 2017	Mar. 06, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	May 18, 2018	Apr. 16, 2018	Dec. 31, 2017
Units Issued, Price per Unit								$ 0.60
Interest Expense, Total				$ 383,000	$ 112,000	$ 743,000	$ 131,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price								$ 0.60	$ 1.61
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000		10,000,000
Proceeds from Long-term Lines of Credit						7,200,000
Debt Instrument, Interest Rate, Stated Percentage			22.00%
Debt Instrument, Convertible, Percentage of Conversion Price			90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date			10 days
Interest Payable				742,000		742,000			$ 657,000	$ 657,000
Interest Expense, Total		$ 122,000		382,000	103,000	742,000
Boyalife W.S.N. [Member]
Distributor Agreement Term	3 years
Distributor Agreement, Renewal Term	2 years
Boyalife Group Ltd. [Member]
Revenue from Related Parties				$ 43,000	$ 0	269,000	$ 0
Boyalife Group Ltd. [Member] | Legal Expenses Reimbursement [Member]
Related Party Transaction, Amounts of Transaction						$ 606,000

Note 5 - Commitments and Cont32

Note 5 - Commitments and Contingencies (Details Textual) - USD ($)	May 18, 2018	Mar. 28, 2018	May 04, 2017	Jun. 30, 2018	Oct. 31, 2017	Jun. 30, 2018
Payment Terms, Severance Compensation						1 year
Short Term Investment Minimum				$ 2,000,000		$ 2,000,000
Stock Issued During Period, Shares, New Issues		609,636
Payments of Stock Issuance Costs	$ 681,000	$ 171,000
Broker Dealer [Member]
Payments of Stock Issuance Costs				150,000
Warrants Issued in Connection with Underwritten Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		304,818
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues		609,636
Tail Commission on Proceeds Received		8.00%
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value			$ 1,000,000
Loss Contingency, Negotiation Condition Bond					$ 1,000,000
Loss Contingency Accrual, Ending Balance				$ 0		$ 0
Minimum [Member]
Period Of Warranty On Products						1 year
Maximum [Member]
Period Of Warranty On Products						2 years

Note 5 - Commitments and Cont33

Note 5 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Balance at December 31, 2017	$ 291,000
Warranties issued during the period	30,000
Settlements made during the period	(216,000)
Changes in liability for pre-existing warranties during the period	(5,000)
Balance at June 30, 2018	$ 100,000

Note 6 - Derivative Obligatio34

Note 6 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Jun. 30, 2016
Class of Warrant or Right, Outstanding	14,300,208		14,300,208		4,828,723
Derivative, Gain (Loss) on Derivative, Net, Total	$ 308,000	$ 44,000	$ 567,000	$ 113,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding						404,412

Note 6 - Derivative Obligatio35

Note 6 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Jun. 30, 2018	Dec. 31, 2017
Measurement Input, Share Price [Member]
Valuation assumption	0.42	3
Measurement Input, Price Volatility [Member]
Valuation assumption	1.112	1.07
Measurement Input, Expected Term [Member]
Valuation assumption	2.7	3.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.026	0.0199
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	8	8

Note 6 - Derivative Obligatio36

Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Derivative obligations	$ 30,000	$ 597,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 30,000	$ 597,000

Note 6 - Derivative Obligatio37

Note 6 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Balance			$ 597,000
Change in fair value of derivative obligation	$ (308,000)	$ (44,000)	(567,000)	$ (113,000)
Balance	$ 30,000		$ 30,000

Note 7 - Stockholders' Equity38

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	May 18, 2018	Mar. 28, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Units Issued, Price per Unit	$ 0.60
Proceeds from Issuance or Sale of Equity, Total	$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net	4,819,000
Payments of Stock Issuance Costs	$ 681,000	$ 171,000
Stock Issued During Period, Shares, New Issues		609,636
Shares Issued, Price Per Share		$ 2.27
Proceeds from Issuance of Common Stock, Net		$ 1,213,000				$ 6,032,000
Allocated Share-based Compensation Expense, Total				$ 163,000	$ 181,000	$ 300,000	$ 428,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						0
Class of Warrant or Right, Outstanding, Intrinsic Value			$ 0	$ 0		$ 0
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.60
Warrants and Rights Outstanding, Term	5 years
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.68
Warrants and Rights Outstanding, Term		5 years 182 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		304,818
Units [Member]
Number of Units Issued	6,475,001
Convertible Units, Number of Common Shares Called by Each Unit	1
Convertible Units, Number of Common Warrants Called by Each Unit	1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Pre-funded Units [member]
Number of Units Issued	2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit	1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit	1
Number of Units Exercised			2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	1,156,027
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.92
Granted, options (in shares) | shares	93,500
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.63
Forfeited (in shares) | shares	(21,875)
Forfeited (in dollars per share) | $ / shares	$ 3.26
Expired, options (in shares) | shares	(27,182)
Expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.67
Outstanding, options (in shares) | shares	1,200,470
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.81
Outstanding, weighted average remaining contractual life, options (Year)	8 years 146 days
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	960,726
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.02
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 36 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	303,348
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 6.26
Exercisable, weighted average remaining contractual life, options (Year)	5 years 182 days
Exercisable, aggregate intrinsic value, options | $

Note 7 - Stockholders' Equity40

Note 7 - Stockholders' Equity - Schedule of Assumptions (Details)	6 Months Ended
	Jun. 30, 2018
Expected life (years) (Year)	5 years 219 days
Risk-free interest rate	2.70%
Expected volatility	98.00%
Dividend yield	0.00%

Note 7 - Stockholders' Equity41

Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Balance, Number of Shares (in shares) | shares	416
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares	$ 17.60
Granted, Number of Shares (in shares) | shares
Granted, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Vested, Number of Shares (in shares) | shares	416
Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 17.60
Forfeited, Number of Shares (in shares) | shares
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares
Balance, Number of Shares (in shares) | shares
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) | $ / shares

Note 7 - Stockholders' Equity42

Note 7 - Stockholders' Equity - Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Balance (in shares) | shares	4,828,723
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.37
Warrants granted (in shares) | shares	9,471,485
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.67
Warrants exercised (in shares) | shares
Warrants exercised (cashless), weighted average exercise price (in dollars per share) | $ / shares
Balance (in shares) | shares	14,300,208
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 3.61
Exercisable at June 30, 2018 (in shares) | shares	13,296,861
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 3.40

Note 8 - Segment Reporting (Det

Note 8 - Segment Reporting (Details Textual)	6 Months Ended
	Jun. 30, 2018
Number of Reportable Segments	2

Note 8 - Segment Reporting - Su

Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Dec. 31, 2017
Net revenues	$ 2,004,000	$ 3,501,000	$ 3,871,000	$ 6,753,000
Cost of revenues	1,641,000	1,973,000	3,156,000	3,848,000
Gross profit	363,000	1,528,000	715,000	2,905,000
Operating expenses	30,868,000	3,260,000	34,477,000	6,800,000
Operating loss	(30,505,000)	(1,732,000)	(33,762,000)	(3,895,000)
Depreciation and amortization	174,000	172,000	333,000	357,000
Impairment of intangible asset	27,202,000	310,000	27,202,000	310,000
Stock-based compensation expense	163,000	181,000	300,000	428,000
Operating loss	(30,505,000)	(1,732,000)	(33,762,000)	(3,895,000)
Goodwill	1,281,000		1,281,000		$ 13,976,000	$ 13,976,000
Total assets	23,243,000		23,243,000			$ 51,111,000
Clinical Development [Member]
Net revenues	46,000		108,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	46,000	113,000	108,000	266,000
Cost of revenues	49,000	111,000	120,000	235,000
Gross profit	(3,000)	2,000	(12,000)	31,000
Operating expenses	28,408,000	1,899,000	29,588,000	3,880,000
Operating loss	(28,411,000)	(1,897,000)	(29,600,000)	(3,849,000)
Depreciation and amortization	69,000	110,000	137,000	226,000
Impairment of intangible asset	27,202,000		27,202,000
Stock-based compensation expense	122,000	100,000	220,000	251,000
Operating loss	(28,411,000)	(1,897,000)	(29,600,000)	(3,849,000)
Goodwill	500,000		500,000
Total assets	12,808,000		12,808,000
Device [Member]
Net revenues	1,958,000		3,763,000
Device [Member] | Operating Segments [Member]
Net revenues	1,958,000	3,388,000	3,763,000	6,487,000
Cost of revenues	1,592,000	1,862,000	3,036,000	3,613,000
Gross profit	366,000	1,526,000	727,000	2,874,000
Operating expenses	2,460,000	1,361,000	4,889,000	2,920,000
Operating loss	(2,094,000)	165,000	(4,162,000)	(46,000)
Depreciation and amortization	105,000	62,000	196,000	131,000
Impairment of intangible asset
Stock-based compensation expense	41,000	81,000	80,000	177,000
Operating loss	(2,094,000)	$ 165,000	(4,162,000)	$ (46,000)
Goodwill	781,000		781,000
Total assets	$ 10,435,000		$ 10,435,000

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2018
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability fom Impairment of Intangible Assets	$ (3,451,000)	$ (3,451,000)
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%

Note 9 - Income Taxes - Summary

Note 9 - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss before benefit for income taxes	$ (30,612,000)	$ (1,827,000)	$ (33,982,000)	$ (3,924,000)
Benefit for income taxes	$ 3,451,000	$ 673,000	$ 3,451,000	$ 673,000
Effective tax rate	11.30%		10.20%